INM vs. IMNN, RLYB, SYBX, AIMD, TXMD, TRIB, NKGN, FLGC, NEUP, and ME
Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Imunon (IMNN), Rallybio (RLYB), Synlogic (SYBX), Ainos (AIMD), TherapeuticsMD (TXMD), Trinity Biotech (TRIB), NKGen Biotech (NKGN), Flora Growth (FLGC), Neuphoria Therapeutics (NEUP), and 23andMe (ME). These companies are all part of the "pharmaceutical products" industry.
InMed Pharmaceuticals vs. Its Competitors
InMed Pharmaceuticals (NASDAQ:INM) and Imunon (NASDAQ:IMNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.
InMed Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Imunon has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500.
Imunon has a consensus target price of $15.50, indicating a potential upside of 2,814.63%. Given Imunon's stronger consensus rating and higher possible upside, analysts clearly believe Imunon is more favorable than InMed Pharmaceuticals.
In the previous week, Imunon had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Imunon and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 1.89 beat Imunon's score of 1.19 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.
InMed Pharmaceuticals has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Imunon shares are owned by institutional investors. 1.4% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Imunon has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. InMed Pharmaceuticals' return on equity of -107.93% beat Imunon's return on equity.
Summary
Imunon beats InMed Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get InMed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InMed Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:INM) was last updated on 7/16/2025 by MarketBeat.com Staff
